Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study - Bagatell, Rochelle; London, Wendy B.; Wagner, Lars M.; Voss, Stephan D.; Stewart, Clinton F.; Maris, John M.; Kretschmar, Cynthia; Cohn, Susan L. (Journal of clinical oncology, 2011)
Keywords: Adolescent; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Camptothecin - administration & dosage; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Child; Child, Preschool; Dacarbazine - administration & dosage; Dacarbazine - adverse effects; Dacarbazine - analogs & derivatives; Disease-Free Survival; Female; Humans; Infant; Male; Medical sciences; Neuroblastoma - drug therapy; Neurology; Original Reports; Tumors; Tumors of the nervous system. Phacomatoses; Camptothecin derivatives; Human; Antineoplastic agent; Nervous system diseases; Relapse; Treatment resistance; Enzyme; DNA topoisomerase; Enzyme inhibitor; Neuroblastoma; Malignant tumor; Irinotecan; Alkylating agent; Isomerases; Cancerology; Treatment; Phase II trial; Temozolomide; Autonomic neuropathy; Topoisomerase I inhibitor; Child; Cancer